News
Eli Lilly says new GLP-1 weight loss pill could reach market in 2026
Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill for FDA approval by the end of the year. The pill does not produce the same amount of weight loss as injections,
Eli Lilly (LLY) reported better than expected earnings for the second quarter Thursday. But disappointing results of its much ...
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.
Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.
On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...
Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / ...
18hon MSN
Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback